Recent Updates
Recently added Catalysts
JSPR Negative Sentiment Score: 20/100

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR

Key Takeaway: Jasper Therapeutics, Inc. is embroiled in a class action lawsuit filed by the DJS Law Group for alleged violations of securities laws. The lawsuit claims the company made misleading statements about its manufacturing processes and clinical trials, potentially impacting investor confidence. Shareholders who purchased shares during a specified period are urged to register for participation. The firm emphasizes that there is no cost to join the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • Jasper Therapeutics is facing a class action lawsuit for securities law violations.
  • The complaint alleges that the company made false and misleading statements regarding its operations.
  • Insufficient controls over third-party manufacturing could jeopardize clinical trials.
  • Shareholders have been encouraged to participate due to reported losses.

Full Press Release Details

LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 30, 2023 to July 3, 2025
DEADLINE: November 18, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Jasper’s controls over third-party manufacturing was insufficient to ensure its vendors followed all applicable rules and regulations. The Company’s clinical trials were placed at risk due to problems with its manufacturing partners. Based on these facts, Jasper’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What is the class action lawsuit against Jasper Therapeutics about?

The lawsuit involves Jasper for making false statements and failing in manufacturing oversight.

What is the class period for the Jasper lawsuit?

The class period runs from November 30, 2023, to July 3, 2025.

What is the deadline to join the class action against Jasper?

The deadline to join is November 18, 2025.

Do I need to be a lead plaintiff to recover losses?

No, being a lead plaintiff is not required to participate in any recovery.

How can shareholders stay updated on the lawsuit?

Shareholders will receive updates through portfolio monitoring software after registering.

Last updated: Nov 4, 2025